Related Experiment Video
Updated: Aug 8, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 18, 2014
[Pseudomonas aeruginosa bacteremia associated with hematologic disorders [III]. Prognostic factors]
Abstract:
We reviewed 57 episodes of Pseudomonas aeruginosa bacteremia in 55 patients with hematologic disorders such as acute leukemia during a 16-year period, focusing especially on the prognosis. Survival at one week after onset was observed in only 39% of the episodes. Prognosis was significantly better in patients with unimicrobial bacteremia than in those with polymicrobial bacteremia (21/42 vs 1/15, p less than 0.01), in patients without shock than in those with shock (13/21 vs 9/36, p less than 0.02), in patients with granulocyte count at onset of at least 100/mm3 than in those with more marked granulocytopenia (10/13 vs 12/44, p less than 0.01), in patients with an increase in granulocyte count by at least 100/mm3 during their infection than in those without any subsequent increase (18/18 vs 4/13, p less than 0.001), and in patients with total serum protein level at onset of at least 6.0 g/dl than in those with hypoproteinemia (18/32 vs 4/25, p less than 0.01). Patients with bacteremia secondary to urogenital infection tended to have a higher one-week survival rate than those with pneumonia followed by bacteremia (4/8, 50% vs 2/9, 22%). With regard to the antibiotic treatment of unimicrobial bacteremia, 14 (70%) of 20 patients receiving therapy with one or two anti-pseudomonal beta-lactam antibiotics and an aminoglycoside in combination that were effective in vitro against the infecting organism survived, and so did only seven (32%) of 22 patients receiving therapy with either one in vitro effective beta-lactam or aminoglycoside or inadequate drugs (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Pseudomonas aeruginosa bacteremia in hematologic disorder patients has a poor prognosis, with only 39% surviving one week. Factors like unimicrobial infection and adequate granulocyte counts improve survival outcomes.
Area of Science:
- Infectious Diseases
- Hematology
- Clinical Microbiology
Context:
- Pseudomonas aeruginosa bacteremia is a serious complication in patients with hematologic disorders, including acute leukemia.
- A 16-year review of 57 episodes provides insights into prognostic factors and treatment efficacy.
Purpose:
- To analyze the prognosis of Pseudomonas aeruginosa bacteremia in patients with hematologic disorders.
- To identify clinical and laboratory factors associated with improved survival.
- To evaluate the impact of antibiotic treatment strategies on patient outcomes.
Summary:
- Survival at one week was low (39%).
- Favorable prognostic factors included unimicrobial bacteremia, absence of shock, higher granulocyte counts at onset and during infection, and adequate serum protein levels.
- Combination antibiotic therapy with in vitro effective anti-pseudomonal beta-lactams and aminoglycosides showed significantly better survival than other regimens.
Impact:
- Identifies key indicators for predicting outcomes in P. aeruginosa bacteremia.
- Highlights the importance of early detection and management of factors like granulocytopenia and hypoproteinemia.
- Informs optimal antibiotic strategies for treating P. aeruginosa bacteremia in immunocompromised patients.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Pneumonia I: Introduction

